Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer
Table 2
Association between the clinicopathological characteristics and prognosis of patients with gastric carcinoma.
Variables
5-year survival (%)
MST (months)
Log-rank
Sex
0.54
Male
41.5
35.2
Female
37.3
26.2
Age
<0.01
<70
45.4
42.2
≥70
26.9
24.3
T stage
<0.01
T1
50.0
50.3†
T2
77.1
48.8†
T3
52.3
69.3
T4
23.9
22.3
N stage
<0.01
N0
71.9
75.2†
N1
58.2
72.2
N2
38.6
27.3
N3
20.2
17.1
Differentiation
<0.01
Middle
58.6
72.2
Low
35.9
26.9
Type
0.25
Adenocarcinoma and others
42.3
31.4
Signet-ring cell
25.6
28.2
Size
0.08
<5 cm
45.4
42.6
≥5 cm
38.6
26.9
Lymph vascular invasion
<0.01
No
57.0
72.18
Yes
35.8
26.94
Neural invasion
<0.01
No
64.3
83.15
Yes
31.8
24.48
Chemotherapy
<0.01
No
32.4
22.28
Yes
51.1
83.15
MMP-7
0.39
—
41.9
35.58
+
37.8
24.81
TIMP-1
0.71
—
41.5
35.15
+
38.1
27.27
TIMP-1&MMP-7
0.18
Both −
41.7
30.82
−/+ or +/−
41.9
42.09
Both +
30.0
17.38
TIMP-1&MMP-7
0.07
Not both +
41.7
37.19
Both +
30.0
17.38
†Mean survival time was provided when MST could not be calculated; MST: median survival time, months; −: negative expression; +: positive expression; both −: patients whose tumour tissue expressed neither MMP-7 nor TIMP-1; −/+: patients whose tumour tissue expressed only TIMP-1; +/−: patients whose tumour tissue expressed only MMP-7; both +: patients whose tumour tissue expressed both MMP-7 and TIMP-1.
